Notice of Q2 and Interim Results

Benchmark Holdings PLC
05 May 2023
 

5 May 2023

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

 

Notice of Q2 and Interim Results

 

Results presentations

 

Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will announce its Q2 and Interims results, for the three and six month period ended 31 March 2023, on Tuesday, 23 May 2023. 

 

Presentation for analysts and institutional investors at 08.00 UK

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a presentation for analysts and institutional investors on the day at 08.00 UK time.

 

A live webcast of the presentation will be available for analysts and investors to join remotely at the following link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230523_3

 

Equity Development webcast at 12.00 UK time

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers on the day at 12.00 UK time. The webcast is open to all existing and potential shareholders.

 

To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-2qresults-presentation-23may2023

 

A recording of the presentation will be available after the event on the Equity Development website.

 

 

  Enquiries

For further information, please contact:


Benchmark Holdings plc

Tel:  0114 240 9939

Trond Williksen, CEO


Septima Maguire, CFO


Ivonne Cantu, Investor Relations






Numis (Broker and NOMAD)

Tel:  020 7260 1000

Freddie Barnfield, Duncan Monteith, Sher Shah




MHP

Tel:  020 3128 8004

Katie Hunt, Reg Hoare, Veronica Farah

benchmark@mhpgroup.com

 

Equity Development

Hannah Crowe

 

Tel:  020 7065 2692


 

 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings